Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22646427 | 0.98 | SLC10A1 (0.34) | POLBALDH1A1PKMNPC1TP53 | |
| SCHEMBL21868845 | 0.94 | MEN1 (0.36) | POLBALDH1A1PKMNPC1TP53 | |
| SCHEMBL21869116 | 0.79 | NPSR1 (0.50) | ALDH1A1PKMNPC1HPGDSLC10A1 | |
| SCHEMBL21868896 | 0.77 | NPSR1 (0.48) | ALDH1A1PKMNPC1HPGDSLC10A1 | |
| SCHEMBL21869099 | 0.76 | ALDH1A1 (0.48) | POLBALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL19900896 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPT | |
| SCHEMBL19900927 | 0.74 | TSHR (0.38) | POLBALDH1A1HPGDHSP90AA1HSD17B10 | |
| SCHEMBL21868893 | 0.74 | ALDH1A1 (0.47) | POLBALDH1A1PKMNPC1HPGD | |
| SCHEMBL21868952 | 0.73 | HSP90AA1 (0.36) | POLBALDH1A1HPGDHSP90AA1HSD17B10 | |
| SCHEMBL21868869 | 0.72 | NPSR1 (0.46) | NPC1SLC10A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | POLB 38/4885ALDH1A1 2589/4885PKM 827/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | POLB 215/4885ALDH1A1 3164/4885PKM 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.